GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Co-Diagnostics Inc (NAS:CODX) » Definitions » Debt-to-EBITDA

Co-Diagnostics (Co-Diagnostics) Debt-to-EBITDA

: -0.07 (As of Dec. 2023)
View and export this data going back to 2017. Start your Free Trial

Debt-to-EBITDA measures a company's ability to pay off its debt.

Co-Diagnostics's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $0.84 Mil. Co-Diagnostics's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $2.15 Mil. Co-Diagnostics's annualized EBITDA for the quarter that ended in Dec. 2023 was $-46.05 Mil. Co-Diagnostics's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 was -0.06.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Co-Diagnostics's Debt-to-EBITDA or its related term are showing as below:

CODX' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -2.06   Med: -0.31   Max: -0.03
Current: -0.07

During the past 9 years, the highest Debt-to-EBITDA Ratio of Co-Diagnostics was -0.03. The lowest was -2.06. And the median was -0.31.

CODX's Debt-to-EBITDA is ranked worse than
100% of 430 companies
in the Medical Devices & Instruments industry
Industry Median: 1.255 vs CODX: -0.07

Co-Diagnostics Debt-to-EBITDA Historical Data

The historical data trend for Co-Diagnostics's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Co-Diagnostics Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-EBITDA
Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - -0.03 -0.07

Co-Diagnostics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Debt-to-EBITDA Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.01 -0.02 -0.07 -0.09 -0.07

Competitive Comparison

For the Medical Devices subindustry, Co-Diagnostics's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Co-Diagnostics Debt-to-EBITDA Distribution

For the Medical Devices & Instruments industry and Healthcare sector, Co-Diagnostics's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Co-Diagnostics's Debt-to-EBITDA falls into.



Co-Diagnostics Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Co-Diagnostics's Debt-to-EBITDA for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(0.838 + 2.152) / -41.476
=-0.07

Co-Diagnostics's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(0.838 + 2.152) / -46.048
=-0.06

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Dec. 2023) EBITDA data.


Co-Diagnostics  (NAS:CODX) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


Co-Diagnostics Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Co-Diagnostics's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Co-Diagnostics (Co-Diagnostics) Business Description

Traded in Other Exchanges
Address
2401 South Foothill Drive, Salt Lake City, UT, USA, 84109
Co-Diagnostics Inc is a molecular diagnostics company. It develops, licenses, and commercializes molecular technologies such as lab systems (MDx device) and manufacture and sell reagents used for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). CDI's low-cost system uses its tests to diagnose tuberculosis, Zika, hepatitis B and C, Malaria, dengue and HIV. The company's diagnostics systems enable very rapid, low-cost, sophisticated molecular testing for organisms and genetic diseases by greatly automating historically complex procedures in both the development and administration of tests.
Executives
Brian Lee Brown officer: Chief Financial Officer 5322 W. BRIAR PARK ROAD, HERRIMAN UT 84096
Ted Murphy director 64 INDUSTRIAL RD., RICHMOND HILL A6 L4C2Y1
Eugene Durenard director 2401 S. FOOTHILL DRIVE SUITE D, SALT LAKE CITY UT 84109
Dwight H Egan director, officer: CEO and President 4049 S. HIGHLAND DRIVE, SALT LAKE CITY UT 84124
Richard S Serbin director 750 LEXINGTON AVENUE, 6TH FLOOR, NEW YORK NY 10022
James B Nelson director 26 WEST MISSION AVENUE, SUITE 8, SANTA BARBARA CA 93010
Reed L Benson officer: CFO and Secretary 7050 UNION PARK CENTER, #600, SALT LAKE CITY UT 84047
Edward L. Murphy director 2401 S. FOOTHILL DRIVE SUITE D, SALT LAKE CITY UT 84109
Brent Satterfield director, officer: Chief Science Officer 4049 S. HIGHLAND DRIVE, SALT LAKE CITY UT 84124
America 2030 Capital, Llc 10 percent owner 1301 SHILOH RD., NW, SUITE 1231, KENNESAW GA 30144
Edward Borkowski director 1500 CORPORATE DRIVE, SUITE 400, CANONSBURG PA 15317
Frank J Kiesner director 4049 S. HIGHLAND DRIVE, SALT LAKE CITY UT 84124
Reagents, Llc 10 percent owner 8160 S. HIGHLAND DR, SANDY UT 84093
Legends Capital Group, Llc 10 percent owner 4049 S. HIGHLAND DRIVE, SALT LAKE CITY UT 84124